Provider perspectives on challenges in treatment during psychedelic therapy.

Area of Science:

• Psychiatry and Mental Health
• Clinical Psychology
• Pharmacology

Background:

• Psychedelic treatments, including psilocybin and LSD, are emerging psychiatric interventions.
• Clinical trial reports often lack detailed exploration of the unique challenges associated with psychedelic-assisted therapies.
• Understanding these challenges is crucial for developing effective treatment protocols.

Purpose of the Study:

• To identify challenges encountered by providers administering psychedelic drugs in research settings.
• To assess provider opinions on potential safeguards to enhance psychedelic treatment outcomes.
• To inform the development of psychological support protocols for psychedelic therapies.

Main Methods:

• An anonymous online survey was distributed to clinicians involved in psilocybin and LSD trials.
• Participants were recruited via clinicaltrials.gov, personal contacts, and snowball sampling.
• Qualitative thematic analysis was used to analyze free-response data on treatment challenges.

Main Results:

• Forty qualified respondents reported on 1656 psychedelic sessions.
• Common challenges included intense dysphoria (42%), disappointment (25%), and re-experiencing trauma (17%).
• 70% of respondents advocated for additional psychological support for patients with PTSD or prior trauma.

Conclusions:

• Psychedelic providers face diverse challenges during treatment sessions.
• These challenges necessitate consideration in the development of psychological support protocols for clinical trials.
• Findings can inform future clinical guidelines for psychedelic-assisted therapies.